Core Problem Statement

Oncology treatments continue to face limitations due to autologous cell therapy processing constraints, creating a clear market demand for scalable off-the-shelf therapeutic models.

Solution Overview

Development and scaling of next-generation gamma-delta T-cell therapies derived from healthy donors. The platform utilizes advanced, clinically aligned cell engineering techniques backed by GMP-ready manufacturing protocols to enable automated allogeneic deployment.